Sitemap

The sitemap below shows the entire contents of the site for your navigation.

• Homepage
• About Us
• Team
• Robert Booth, BA, FCMA
• Matthew Gregory, PhD
• Edward Hodgkin, D.Phil
• Christine Martin, D.Phil
• Melanie McCullagh, D.Phil, MBA
• Steven Moss, PhD
• Barrie Wilkinson, PhD
• Board
• Mark Lampert, AB, MBA
• Peter Leadlay, PhD, FRS
• Alan Lewis, PhD
• Peter Ringrose, PhD
• Marc Schneidman, BA, JD
• Edward Hodgkin, D.Phil
• Advisors
• Prof. Jean-Michel Pawlotsky
• Dr John Dixon
• Dr Johan Neyts
• Dr Roy Eady
• Prof. Peter Leadlay
• History
• Careers
• We currently have no vacancies
• Contact
• Pipeline
• Pipeline overview
• nPT-mTOR
• nPT-CLN
• nPT-ery
• nPT-CyP
• Exploratory projects
• Clinically validated lead exploration
• Cancer drug discovery
• Antibacterial drug discovery
• Strategy
• Exploiting polyketides
• Business strategy
• Project selection
• Blockbuster potential
• Biotica exclusivity
• Clinical validation
• Expert advisors
• News
• Partnering
• Partnering with Biotica
• Technology
• novoPT™
• Polyketides as leads
• Validation of polyketides as a therapeutic class
• Targets addressable by polyketides
• Polyketide library
• Lead optimisation
• Presentation illustrating novoPT™ lead optimisation technology
• Disclaimer